Literature DB >> 18650228

Active systemic lupus erythematosus is associated with failure of antigen-presenting cells to express programmed death ligand-1.

N Mozaffarian1, A E Wiedeman, A M Stevens.   

Abstract

OBJECTIVE: Antigen-presenting cells (APC) play critical roles in establishing and maintaining peripheral tolerance. This is accomplished in part via expression of negative co-stimulatory molecules such as programmed death ligand-1 (PD-L1) on tolerogenic APC, such as immature myeloid dendritic cells (mDC). Several studies have strongly linked dysfunction of APC, including mDC, to the pathogenesis of SLE. The objective of this study was to determine whether APC expressed PD-L1 protein at normal levels during active lupus.
METHODS: Peripheral blood mononuclear cells (PBMC) were isolated from 19 paediatric patients with SLE and from 17 healthy age-matched controls. PBMC from both cohorts were cultured in the absence of exogenously added stimuli, and leucocyte PD-L1 expression was measured by flow cytometry.
RESULTS: Immature mDC and monocytes (Mo) from healthy children expressed little PD-L1 at initial isolation, but spontaneously up-regulated PD-L1 by 24 h. In contrast, both mDC and Mo from patients with active SLE failed to up-regulate PD-L1 over a 5 day time course, expressing this protein only during disease remissions.
CONCLUSIONS: These data are the first to link active lupus with reversibly decreased PD-L1 expression on professional APC, suggesting a novel mechanism for loss of peripheral tolerance in SLE.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18650228      PMCID: PMC2722808          DOI: 10.1093/rheumatology/ken256

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN: 1462-0324            Impact factor:   7.580


  51 in total

1.  B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion.

Authors:  H Dong; G Zhu; K Tamada; L Chen
Journal:  Nat Med       Date:  1999-12       Impact factor: 53.440

2.  Lymphopenia is associated with neuropsychiatric manifestations and disease activity in paediatric systemic lupus erythematosus patients.

Authors:  H-H Yu; L-C Wang; J-H Lee; C-C Lee; Y-H Yang; B-L Chiang
Journal:  Rheumatology (Oxford)       Date:  2007-08-01       Impact factor: 7.580

3.  The validity of the ECLAM index for the retrospective evaluation of disease activity in systemic lupus erythematosus.

Authors:  M Mosca; W Bencivelli; C Vitali; P Carrai; R Neri; S Bombardieri
Journal:  Lupus       Date:  2000       Impact factor: 2.911

4.  Immature myeloid and plasmacytoid dendritic cells infiltrate renal tubulointerstitium in patients with lupus nephritis.

Authors:  Nicoletta Fiore; Giuseppe Castellano; Antonella Blasi; Carmen Capobianco; Antonia Loverre; Vincenzo Montinaro; Stefano Netti; Diletta Torres; Carlo Manno; Giuseppe Grandaliano; Elena Ranieri; Francesco Paolo Schena; Loreto Gesualdo
Journal:  Mol Immunol       Date:  2007-06-13       Impact factor: 4.407

5.  Programmed death-1 ligands-transfected dendritic cells loaded with glutamic acid decarboxylase 65 (GAD65) inhibit both the alloresponse and the GAD65-reactive lymphocyte response.

Authors:  F-R He; H-F Zhu; H Huang; Y D Dai; X Shen; M Wang; L Li; W Xing; G-X Shen
Journal:  Clin Exp Immunol       Date:  2007-11-15       Impact factor: 4.330

6.  Upregulation of PD-1 expression on circulating and intrahepatic hepatitis C virus-specific CD8+ T cells associated with reversible immune dysfunction.

Authors:  Lucy Golden-Mason; Brent Palmer; Jared Klarquist; John A Mengshol; Nicole Castelblanco; Hugo R Rosen
Journal:  J Virol       Date:  2007-06-13       Impact factor: 5.103

7.  Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses.

Authors:  Manish J Butte; Mary E Keir; Theresa B Phamduy; Arlene H Sharpe; Gordon J Freeman
Journal:  Immunity       Date:  2007-07-12       Impact factor: 31.745

8.  Involvement of the programmed death-1/programmed death-1 ligand pathway in CD4+CD25+ regulatory T-cell activity to suppress alloimmune responses.

Authors:  Yusuke Kitazawa; Masayuki Fujino; Quanxing Wang; Hiromitsu Kimura; Miyuki Azuma; Masato Kubo; Ryo Abe; Xiao-Kang Li
Journal:  Transplantation       Date:  2007-03-27       Impact factor: 4.939

9.  Association of PDCD1 genetic variation with risk and clinical manifestations of systemic lupus erythematosus in a multiethnic cohort.

Authors:  C M Thorburn; L Prokunina-Olsson; K A Sterba; R F Lum; M F Seldin; M E Alarcon-Riquelme; L A Criswell
Journal:  Genes Immun       Date:  2007-03-08       Impact factor: 2.676

10.  Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation.

Authors:  G J Freeman; A J Long; Y Iwai; K Bourque; T Chernova; H Nishimura; L J Fitz; N Malenkovich; T Okazaki; M C Byrne; H F Horton; L Fouser; L Carter; V Ling; M R Bowman; B M Carreno; M Collins; C R Wood; T Honjo
Journal:  J Exp Med       Date:  2000-10-02       Impact factor: 14.307

View more
  31 in total

Review 1.  PD-1 immunobiology in systemic lupus erythematosus.

Authors:  Colleen S Curran; Sarthak Gupta; Ignacio Sanz; Elad Sharon
Journal:  J Autoimmun       Date:  2018-11-03       Impact factor: 7.094

Review 2.  Contribution of dendritic cells to the autoimmune pathology of systemic lupus erythematosus.

Authors:  Juan P Mackern-Oberti; Carolina Llanos; Claudia A Riedel; Susan M Bueno; Alexis M Kalergis
Journal:  Immunology       Date:  2015-10-12       Impact factor: 7.397

Review 3.  Toward Small-Molecule Inhibition of Protein-Protein Interactions: General Aspects and Recent Progress in Targeting Costimulatory and Coinhibitory (Immune Checkpoint) Interactions.

Authors:  Damir Bojadzic; Peter Buchwald
Journal:  Curr Top Med Chem       Date:  2018       Impact factor: 3.295

Review 4.  New insights into the immunopathogenesis of systemic lupus erythematosus.

Authors:  George C Tsokos; Mindy S Lo; Patricia Costa Reis; Kathleen E Sullivan
Journal:  Nat Rev Rheumatol       Date:  2016-11-22       Impact factor: 20.543

5.  Mature cystic fibrosis airway neutrophils suppress T cell function: evidence for a role of arginase 1 but not programmed death-ligand 1.

Authors:  Sarah A Ingersoll; Julie Laval; Osric A Forrest; Marcela Preininger; Milton R Brown; Dalia Arafat; Greg Gibson; Vin Tangpricha; Rabindra Tirouvanziam
Journal:  J Immunol       Date:  2015-04-29       Impact factor: 5.422

6.  Functional characterization of peripheral blood dendritic cells and monocytes in systemic lupus erythematosus.

Authors:  Ana Henriques; Luís Inês; Tiago Carvalheiro; Maura Couto; Angela Andrade; Susana Pedreiro; Paula Laranjeira; José Mário Morgado; Maria Luísa Pais; José António Pereira da Silva; Artur Paiva
Journal:  Rheumatol Int       Date:  2011-01-08       Impact factor: 2.631

7.  Programmed cell death ligand 1 (PD-L1) expression on gastric cancer and its relationship with clinicopathologic factors.

Authors:  Lin Zhang; Miaozhen Qiu; Ying Jin; Jiao Ji; Baoxia Li; Xueping Wang; Shumei Yan; Ruihua Xu; Dajun Yang
Journal:  Int J Clin Exp Pathol       Date:  2015-09-01

Review 8.  PD-L1 and B7-1 Cis-Interaction: New Mechanisms in Immune Checkpoints and Immunotherapies.

Authors:  Christopher D Nishimura; Marc C Pulanco; Wei Cui; Liming Lu; Xingxing Zang
Journal:  Trends Mol Med       Date:  2020-11-13       Impact factor: 11.951

9.  Effect of immune tolerance induced by immature dendritic cells and CTLA4-Ig on systemic lupus erythematosus: An in vivo study.

Authors:  Cuili Huang; Lidan Zhang; Fang Ling; Sijian Wen; Yanyan Luo; Hui Liu; Jingping Liu; Wenjun Zheng; Ming Liang; Jian Sun; You-Kun Lin
Journal:  Exp Ther Med       Date:  2018-01-04       Impact factor: 2.447

10.  Comparison of biomarkers for systemic juvenile idiopathic arthritis.

Authors:  Susan Shenoi; Jing-Ni Ou; Chester Ni; Claudia Macaubas; Vivian H Gersuk; Carol A Wallace; Elizabeth D Mellins; Anne M Stevens
Journal:  Pediatr Res       Date:  2015-08-12       Impact factor: 3.756

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.